Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae isolates cultured from Japanese adult patients with community-acquired pneumonia in Goto City, Japan.

Autor:	Miyazaki T; Nagasaki University, Nagasaki, Japan.; Division of Respirology, Rheumatology, Infectious Diseases, and Neurology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan., van der Linden M; German Reference Laboratory for Streptococci, Department of Medical Microbiology, University Hospital RWTH, Aachen, Germany., Hirano K; Nagasaki University, Nagasaki, Japan.; National Center for Global Health and Medicine, Tokyo, Japan., Maeda T; Nagasaki University, Nagasaki, Japan., Kohno S; Nagasaki University, Nagasaki, Japan., Gonzalez EN; Pfizer Inc., Collegeville, PA, United States., Zhang P; Pfizer Inc., Collegeville, PA, United States., Isturiz RE; Pfizer Inc., Collegeville, PA, United States., Gray SL; Pfizer Inc., Collegeville, PA, United States., Grant LR; Pfizer Inc., Collegeville, PA, United States., Pride MW; Pfizer Inc., Pearl RiverNew York, NY, United States., Gessner BD; Pfizer Inc., Collegeville, PA, United States., Jodar L; Pfizer Inc., Collegeville, PA, United States., Arguedas AG; Pfizer Inc., Collegeville, PA, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in microbiology [Front Microbiol] 2024 Sep 24; Vol. 15, pp. 1458307. Date of Electronic Publication: 2024 Sep 24 (Print Publication: 2024).
DOI:	10.3389/fmicb.2024.1458307
Abstrakt:	Streptococcus pneumoniae is an important cause of community-acquired pneumonia (CAP) in Japan. Here, we report the serotype distribution and antimicrobial susceptibility of cultured pneumococcal isolates from Japanese adults aged ≥18 years with CAP. This was a prospective, population-based, active surveillance study conducted in Goto City, Japan from December 2015 to November 2020. Pneumococcal isolates from sterile sites (blood and pleural fluid) and non-sterile sites (sputum and bronchoalveolar lavage) were cultured as part of the standard of care. S. pneumoniae were serotyped using the Quellung reaction. Antimicrobial susceptibility was tested using microdilution and interpreted according to the Clinical and Laboratory Standards Institute criteria. Isolates resistant to erythromycin were phenotyped using the triple-risk test and genotyped by polymerase chain reaction. A total of 156 pneumococcal isolates were collected (138 from sputum, 15 from blood, and 3 from bronchoalveolar lavage) from 1992 patients. Of these, 142 were non-duplicate isolates from unique patients and were included in the analyses. Serotypes contained within the 13-valent pneumococcal conjugate vaccine (PCV13) (including 6C), PCV15 (including 6C), and PCV20 (including 6C and 15C) were detected in 39 (27%), 45 (32%), and 80 (56%) of 142 isolates, respectively. The most common serotypes were 35B (12%), 11A (11%), and 3 (11%). Multidrug resistance (MDR) was detected in 96/142 (68%) isolates. Of the 96 MDR isolates, 31, 32, and 59% were PCV13, PCV15, and PCV20 serotypes, respectively; the most common MDR serotypes were 35B (16%), 6C, 10A, and 15A (9% each), and 3 and 11A (8% each). A total of 119 isolates were resistant to macrolides; 41 (35%) had an M phenotype, 53 (45%) had an iMcLS phenotype, and 25 (21%) had a cMLS phenotype. In conclusion, pneumococcal serotypes 35B, 11A and 3 were most frequently associated with pneumonia and antimicrobial resistance was common among pneumococcal isolates from adults with CAP in Goto City, Japan. Implementing higher-valency PCVs May help reduce vaccine-type CAP among Japanese adults. Competing Interests: EG, PZ, RI, SG, LG, BG, LJ, and AA were employed by Pfizer, NY. MP was employed by Pfizer, PA. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2024 Miyazaki, van der Linden, Hirano, Maeda, Kohno, Gonzalez, Zhang, Isturiz, Gray, Grant, Pride, Gessner, Jodar and Arguedas.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu